» Articles » PMID: 26685760

Elevations in C-reactive Protein and Endothelin-1 System Activity in Humans

Overview
Journal Life Sci
Publisher Elsevier
Date 2015 Dec 22
PMID 26685760
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Aims: C-reactive protein (CRP) is an inflammatory cytokine that has been shown to be an independent predictor of future atherothrombotic events. Hyperactivity of endothelin-1 (ET-1), a potent vasoconstrictor peptide produced by the endothelium, is linked with cardiovascular disease development and progression. ET-1 is sensitive to inflammatory stimuli, though the influence of CRP on ET-1 system activity is unknown. We tested the hypothesis that ET-1-mediated vasoconstrictor tone is enhanced in adults with elevated plasma CRP concentrations.

Materials And Methods: Sixty non-obese adults (43-70years) were studied: 20 with hsCRP<1.0mg/L (low CRP; 0.5±0.1mg/L); 20 with hsCRP 1.0-3.0mg/L (moderate CRP; 2.0±0.1mg/L); and 20 with hsCRP>3.0mg/L (high CRP; 6.3±0.5mg/L). Forearm blood flow (FBF; plethysmography) was determined in response to intra-arterial infusions of ET-1 (5pmol/min for 20min) and selective ETA receptor blockade (BQ-123, 100nmol/min for 60min).

Key Findings: In response to ET-1, FBF decreased ~10% in the low (-10.0±2.3%), moderate (-10.7±4.0%), and high (-6.6±5.2%) CRP groups, with no significant differences between groups. Additionally, all groups demonstrated a marginal, though significant (~10%), vasodilator response to BQ-123; however, there were no differences in the FBF response to BQ-123 across CRP groups. There were no significant correlations between plasma CRP concentrations and peak FBF response to either ET-1 or BQ-123.

Significance: These results indicate that ET-1 system activity is not influenced by elevations in CRP. Enhanced ET-1 system activity may not be involved in the increased cardiovascular disease risk associated with elevations in plasma CRP concentrations.

Citing Articles

Crucial Interactions between Altered Plasma Trace Elements and Fatty Acids Unbalance Ratio to Management of Systemic Arterial Hypertension in Diabetic Patients: Focus on Endothelial Dysfunction.

Gouaref I, Otmane A, Makrelouf M, Abderrhmane S, Haddam A, Koceir E Int J Mol Sci. 2024; 25(17).

PMID: 39273236 PMC: 11395650. DOI: 10.3390/ijms25179288.


C-Reactive Protein in Atherosclerosis-More than a Biomarker, but not Just a Culprit.

Kirkgoz K Rev Cardiovasc Med. 2024; 24(10):297.

PMID: 39077585 PMC: 11262456. DOI: 10.31083/j.rcm2410297.


Expression of the Endothelin-1 Gene and Its Type a Receptor including Physical Activity among Patients with Acute Myocardial Infarction.

Dabek J, Piotrkowicz J, Glogowska-Ligus J, Domagalska-Szopa M, Szopa A, Schreiber L Int J Environ Res Public Health. 2022; 19(12).

PMID: 35742539 PMC: 9224255. DOI: 10.3390/ijerph19127289.


Endothelin and the Cardiovascular System: The Long Journey and Where We Are Going.

Haryono A, Ramadhiani R, Ryanto G, Emoto N Biology (Basel). 2022; 11(5).

PMID: 35625487 PMC: 9138590. DOI: 10.3390/biology11050759.


Synergistic effect of renalase and chronic kidney disease on endothelin-1 in patients with coronary artery disease ‒ a cross-sectional study.

Li Y, Sheu W, Lee W, Wang J, Fu C, Liang K Sci Rep. 2018; 8(1):7378.

PMID: 29743680 PMC: 5943599. DOI: 10.1038/s41598-018-25763-4.

References
1.
Yu Q, Li Y, Wang Y, Zhao S, Yang P, Chen Y . C-reactive protein levels are associated with the progression of atherosclerotic lesions in rabbits. Histol Histopathol. 2012; 27(4):529-35. DOI: 10.14670/HH-27.529. View

2.
Zwaka T, Hombach V, Torzewski J . C-reactive protein-mediated low density lipoprotein uptake by macrophages: implications for atherosclerosis. Circulation. 2001; 103(9):1194-7. DOI: 10.1161/01.cir.103.9.1194. View

3.
Jones G, van Rij A, Solomon C, Thomson I, Packer S . Endothelin-1 is increased overlying atherosclerotic plaques in human arteries. Atherosclerosis. 1996; 124(1):25-35. DOI: 10.1016/0021-9150(95)05773-0. View

4.
Tondi P, Santoliquido A, Di Giorgio A, Sestito A, Sgueglia G, Flore R . Endothelial dysfunction as assessed by flow-mediated dilation in patients with cardiac syndrome X: role of inflammation. Eur Rev Med Pharmacol Sci. 2011; 15(9):1074-7. View

5.
Weil B, Greiner J, DeSouza C, Stauffer B . Relation of C-reactive protein to endothelial fibrinolytic function in healthy adults. Am J Cardiol. 2011; 108(11):1675-9. PMC: 3285466. DOI: 10.1016/j.amjcard.2011.07.026. View